Role of Body Composition in the Prediction of Skeletal Fragility Induced by Hormone Deprivation Therapies in Cancer Patients.
Body composition
Bone health
Breast cancer
Hormonal deprivation
Prostate cancer
Sarcopenic obesity
Journal
Current oncology reports
ISSN: 1534-6269
Titre abrégé: Curr Oncol Rep
Pays: United States
ID NLM: 100888967
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
accepted:
01
08
2023
pubmed:
25
8
2023
medline:
25
8
2023
entrez:
25
8
2023
Statut:
ppublish
Résumé
This review paper is intended to show that changes in body composition are key in the pathogenesis of bone fragility amongst patients with breast and prostate cancer receiving hormone deprivation therapies (HDTs) and that the mechanism is based on the development of alterations in bone quality rather than in bone quantity. Preclinical and clinical data suggest a tight connection amongst bone, adipose and muscular tissues by means of several soluble mediators, potentially leading to (1) bone resorption and bone quality deterioration in sarcopenic obese subjects, (2) bone mineral deposition in healthy trained subjects. Cancer patients treated with HDTs frequently fall into the first condition, named osteosarcopenic obesity. Current clinical guidelines for the prevention of treatment-induced osteoporosis focus on bone mineral density (BMD) as a main predictive factor for fracture risk; however, the pathophysiology underlying HDT-induced bone fragility differs from that of primary and postmenopausal osteoporosis, suggesting a prevalent role for bone quality alterations. Focusing on available data from clinical trials, in our review we suggest osteosarcopenic obesity as a common target for the prevention and treatment of HDTs-related metabolic and skeletal complications, beyond a BMD-centred approach.
Identifiants
pubmed: 37624550
doi: 10.1007/s11912-023-01447-9
pii: 10.1007/s11912-023-01447-9
pmc: PMC10556180
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1141-1152Informations de copyright
© 2023. The Author(s).
Références
Obesity (Silver Spring). 2009 Aug;17(8):1534-41
pubmed: 19629060
Breast Cancer Res Treat. 2020 Jul;182(1):187-193
pubmed: 32399742
Arch Osteoporos. 2022 Jun 3;17(1):82
pubmed: 35654981
J Bone Miner Res. 2022 Apr;37(4):700-710
pubmed: 35038186
PLoS One. 2016 Oct 10;11(10):e0164385
pubmed: 27723820
Proc Nutr Soc. 2020 Jul 16;:1-13
pubmed: 32669148
Bone Rep. 2023 Jan 11;18:101654
pubmed: 36700242
Geroscience. 2021 Feb;43(1):85-110
pubmed: 33528828
Cell Mol Life Sci. 2014 Feb;71(3):493-7
pubmed: 23934155
Ann N Y Acad Sci. 2017 Dec;1410(1):93-106
pubmed: 29265417
J Cachexia Sarcopenia Muscle. 2022 Apr;13(2):781-794
pubmed: 35106971
Ann Oncol. 2021 Dec;32(12):1475-1495
pubmed: 34678411
PLoS One. 2022 Feb 15;17(2):e0263918
pubmed: 35167609
Cytokine Growth Factor Rev. 2004 Feb;15(1):49-60
pubmed: 14746813
Bone. 2017 Apr;97:147-152
pubmed: 28104509
J Cell Biochem. 2009 Feb 1;106(2):232-46
pubmed: 19115254
Endocrine. 2014 Mar;45(2):165-77
pubmed: 23990248
Andrology. 2020 Nov;8(6):1699-1704
pubmed: 32558374
J Bone Miner Res. 2014 Feb;29(2):487-93
pubmed: 23873741
Ageing Res Rev. 2014 May;15:51-60
pubmed: 24632496
J Orthop Surg Res. 2011 Jun 15;6:30
pubmed: 21676245
Breast Cancer Res Treat. 2021 Aug;189(1):145-154
pubmed: 34089422
J Endocrinol Invest. 2022 Jan;45(1):69-77
pubmed: 34255310
Nutr Rev. 2010 Jul;68(7):375-88
pubmed: 20591106
N Engl J Med. 2017 May 18;376(20):1943-1955
pubmed: 28514618
J Endocrinol Invest. 2023 Jul 17;:
pubmed: 37458931
Aging Cell. 2022 Jun;21(6):e13621
pubmed: 35509177
Nutr Res. 2017 Mar;39:1-13
pubmed: 28385284
Osteoporos Int. 2019 Jan;30(1):115-125
pubmed: 30324413
Horm Mol Biol Clin Investig. 2014 Jan;17(1):39-51
pubmed: 25372729
Br J Nutr. 2020 Nov 28;124(10):1102-1113
pubmed: 32616084
PLoS One. 2019 Apr 2;14(4):e0214153
pubmed: 30939140
Ann Oncol. 2020 Sep;31(9):1119-1134
pubmed: 32593798
J Clin Invest. 2003 Dec;112(12):1821-30
pubmed: 14679177
Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6309s-6314s
pubmed: 17062720
Osteoporos Int. 2017 Oct;28(10):2781-2790
pubmed: 28733716
J Clin Oncol. 2019 Nov 1;37(31):2916-2946
pubmed: 31532726
J Endocrinol Invest. 2023 Jul;46(7):1283-1304
pubmed: 36918505
J Intern Med. 2012 Oct;272(4):317-29
pubmed: 22702419
Osteoporos Sarcopenia. 2017 Jun;3(2):98-103
pubmed: 30775511
J Clin Endocrinol Metab. 2022 Nov 25;107(12):3398-3407
pubmed: 35971857
Breast Cancer Res Treat. 2011 Jun;127(2):447-56
pubmed: 21424279
Prostate Cancer Prostatic Dis. 2009;12(4):333-8
pubmed: 19901933
Ann Oncol. 2020 Dec;31(12):1650-1663
pubmed: 32801018
Exp Gerontol. 2010 Sep;45(9):679-84
pubmed: 20433916
J Clin Oncol. 2020 Oct 10;38(29):3363-3366
pubmed: 32603244
Lancet Oncol. 2019 Mar;20(3):339-351
pubmed: 30795951
Prostate Cancer Prostatic Dis. 2022 Apr;25(4):797
pubmed: 34811500
J Cell Biochem. 2019 Sep;120(9):14262-14273
pubmed: 31106446
J Endocrinol Invest. 2019 Nov;42(11):1337-1343
pubmed: 31127591
Curr Osteoporos Rep. 2020 Aug;18(4):388-400
pubmed: 32529456
J Cachexia Sarcopenia Muscle. 2014 Sep;5(3):183-92
pubmed: 24740742
Ageing Res Rev. 2017 May;35:200-221
pubmed: 27702700
J Bone Oncol. 2022 Mar 09;33:100421
pubmed: 35310388
JBMR Plus. 2020 Dec 21;5(2):e10440
pubmed: 33615109
JAMA Netw Open. 2019 Sep 4;2(9):e1911080
pubmed: 31560383
Gastroenterology. 2007 May;132(6):2169-80
pubmed: 17498510
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
J Clin Densitom. 2011 Jul-Sep;14(3):348-53
pubmed: 21723763
Endocrine. 2015 Sep;50(1):223-30
pubmed: 25588772
Osteoporos Int. 2012 Nov;23(11):2567-76
pubmed: 22270857
Curr Osteoporos Rep. 2015 Feb;13(1):1-8
pubmed: 25515697
Curr Opin Clin Nutr Metab Care. 2016 Jan;19(1):31-6
pubmed: 26418824
Bonekey Rep. 2016 Jul 20;5:826
pubmed: 27579164
Osteoporos Int. 2020 Jun;31(6):1125-1133
pubmed: 32108240